Main > INFECTIOUS DISEASES > USA. A. ABSSSI>Treat.>LGP>

---

USA. A. ABSSSI>Treat.>LGP>'s subsections
(*) CA Approval Date: 2018. 09.10.
(*) EU Approval Date: 2015. 02.
(*) FI Launch Date: 2017. 10.30.
(*) FR Launch Date: 2017. 03.03.
(*) IE Launch Date: 2017. 10.30.
(*) SE Launch Date: 2017. 10.30.
(*) UK Launch Date: 2016. 12.08.
(*) USA Approval Date: 2014. 05.23
(*) USA Launch Date: ?
*) USA Approval Date: 2021. 07.23>
>Antibiotic for Inj.
Company
Company Licensee CA
Company Licensee EU
Generic Name: DalbaVancin.HCl
LGP: LipoGlycoPeptide
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 4
Patent>UpDate: 2021. 07.20.
RTM (USA)
RTM (USA) Web-Site
TM (Ex. USA)

USA. A. ABSSSI>Treat.>LGP>'s products
This section has no products